RESULTS OF ALENDRONATE TREATMENT IN PATIENTS DIAGNOSED
WITH ASEPTIC OSTEONECROSIS OF THE FEMORAL HEAD
KAMAL CONSTANTIN KAMAL 1#, DRAGOȘ OVIDIU ALEXANDRU 2*, OTILIA CONSTANTINA ROGOVEANU3, DIANA KAMAL 4#, ALICE SANDRA BUTEICĂ 5#, TUDOR ADRIAN BĂLŞEANU6, CAMELIA PĂNUȘ 7, DANIELA TEODORA MARIA 8#, MAGDALENA RODICA TRĂISTARU 3
1Family Medicine Department, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
2Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St.,
200349, Craiova, Romania
3Physical and Rehabilitation Medicine Department, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St.,
200349, Craiova, Romania
4Physical and Rehabilitation Medicine Department, Medical Clinic Elga, University of Medicine and Pharmacy of Craiova,
2 Mihai Eminescu Str., 200131, Craiova, Romania
5Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
6Department of Physiology, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
7Department of Diabetes, Nutrition and Metabolic Disease, Emergency Clinical County Hospital of Craiova, University of
Medicine and Pharmacy of Craiova, 1Tabaci St., 200642, Craiova, Romania
8Nephrology Department, University of Medicine and Pharmacy of Craiova, 2-4 Petru Rares St., 200349, Craiova, Romania
*corresponding author: dragosado@yahoo.com
#authors with equal contribution
Download Full Article

Abstract:
Aseptic osteonecrosis of the femoral head is a disabling condition with plurifactorial aetiology, which affects especially
young adults. The purpose of the study was to show that alendronate therapy is useful to these patients. We included 34
patients aged 23 to 62 years old, diagnosed in the evolutionary stages II and III, which were divided into two groups. Patients
in the first group received treatment with alendronate-70 mg per week plus 5600 IU cholecalciferol for 2 years and
conservative treatment. Group II was not treated with alendronate but only conservatively treated. Patients were evaluated
from a clinical, imagistic and functional standpoint. In the final evaluation, the imaging aspects improved in patients in the
first group. The dual-energy x-ray absorptiometry (DXA) T score, the visual analogue scale (VAS) and the Harris Hip test
statistically increased significantly in patients in the first group.

Top